시가총액: $3.774T 1.890%
거래량(24시간): $117.0644B 9.650%
  • 시가총액: $3.774T 1.890%
  • 거래량(24시간): $117.0644B 9.650%
  • 공포와 탐욕 지수:
  • 시가총액: $3.774T 1.890%
암호화
주제
암호화
소식
cryptostopics
비디오
최고의 뉴스
암호화
주제
암호화
소식
cryptostopics
비디오
bitcoin
bitcoin

$114720.362772 USD

-0.06%

ethereum
ethereum

$3679.931631 USD

3.08%

xrp
xrp

$3.057833 USD

1.50%

tether
tether

$0.999889 USD

-0.02%

bnb
bnb

$766.427054 USD

1.33%

solana
solana

$169.325846 USD

3.04%

usd-coin
usd-coin

$0.999801 USD

0.01%

tron
tron

$0.334792 USD

2.22%

dogecoin
dogecoin

$0.208867 USD

3.09%

cardano
cardano

$0.753413 USD

1.95%

hyperliquid
hyperliquid

$38.743306 USD

0.17%

stellar
stellar

$0.410709 USD

-0.43%

sui
sui

$3.557841 USD

1.67%

chainlink
chainlink

$16.944222 USD

1.95%

bitcoin-cash
bitcoin-cash

$571.484092 USD

3.65%

암호화폐 뉴스 기사

iotaMotion Announces First Use of its iotaSOFT® Insertion System Outside the United States

2025/05/13 23:14

iotaMotion Announces First Use of its iotaSOFT® Insertion System Outside the United States

iotaMotion, Inc., a pioneer in robotic-assisted systems for cochlear implant surgery, today announced the first use of the iotaSOFT® Insertion System outside of the United States. The technology is currently being applied as part of a pre-market clinical investigation at University Hospital of Zurich, headed by Professor Alexander Huber. This study marks a significant step in expanding access to iotaMotion's innovative technology, which is designed to optimize the precision and safety of cochlear implant surgery.

The iotaSOFT® Insertion System, already commercialized in the United States, offers a unique robotic-assisted approach to inserting electrode arrays used in cochlear implants. The system is designed to provide extremely slow and consistent insertion, which is particularly important for preserving delicate intracochlear structures and enabling optimal positioning of the electrode array. Moreover, the system's advanced capabilities allow for real-time monitoring of ECochG signals, enabling surgeons to make dynamic adjustments to insertion parameters to achieve optimal electrode placement.

"We are thrilled to see the first use of the iotaSOFT® Insertion System outside of the United States at such a prestigious institution as University Hospital of Zurich," stated Mike Lobinsky, President & CEO of iotaMotion. "The team at Zurich has been an exceptional partner, and we look forward to continuing our relationship as we work together to advance cochlear implant care and explore techniques that have never been used in a clinical setting prior to this study."

iotaMotion is committed to expanding the availability of its robotic-assisted systems to surgeons and patients worldwide. The company's mission is to empower surgeons with the tools they need to perform surgery with unmatched precision and control, ultimately leading to better outcomes for patients.

"This collaboration with iotaMotion aligns perfectly with our commitment to pushing the boundaries of hearing health technology and improving the lives of patients with hearing loss," added Professor Huber. "We are honored to be the first center in Europe to introduce this groundbreaking system and contribute to its global launch."

iotaMotion, Inc. is a privately held company headquartered in St. Paul, MN, focused on developing and commercializing robotic-assisted systems for cochlear implant surgery. The company's mission is to revolutionize cochlear implant surgery by harnessing robotic technology to enhance the precision, safety, and effectiveness of surgical procedures.iotaMotion, Inc. is a privately held company headquartered in St. Paul, MN, dedicated to advancing cochlear implant surgery beyond human capability through robotic-assisted solutions. Its flagship technology, the iotaSOFT® Insertion System, is designed to provide a slow and consistent electrode array insertion that is designed to preserve delicate intracochlear structures and optimize the insertion for optimal IV stimulation. The system is commercially available in the United States and currently undergoing a pre-market clinical investigation in other global markets. For more information, visit www.iotamotion.com or contact Wade Colburn, Vice President of Marketing and Clinical, at pr@iotamotion.com.

원본 소스:yahoo

부인 성명:info@kdj.com

제공된 정보는 거래 조언이 아닙니다. kdj.com은 이 기사에 제공된 정보를 기반으로 이루어진 투자에 대해 어떠한 책임도 지지 않습니다. 암호화폐는 변동성이 매우 높으므로 철저한 조사 후 신중하게 투자하는 것이 좋습니다!

본 웹사이트에 사용된 내용이 귀하의 저작권을 침해한다고 판단되는 경우, 즉시 당사(info@kdj.com)로 연락주시면 즉시 삭제하도록 하겠습니다.

2025年08月05日 에 게재된 다른 기사